Your browser doesn't support javascript.
loading
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.
Bédard, Philippe L; Davies, Michael A; Kopetz, Scott; Juric, Dejan; Shapiro, Geoffrey I; Luke, Jason J; Spreafico, Anna; Wu, Bin; Castell, Christelle; Gomez, Corinne; Cartot-Cotton, Sylvaine; Mazuir, Florent; Dubar, Michel; Micallef, Sandrine; Demers, Brigitte; Flaherty, Keith T.
Afiliación
  • Bédard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Davies MA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kopetz S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Juric D; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Luke JJ; Department of Medicine, University of Chicago Cancer Center, Chicago, Illinois.
  • Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Wu B; Department of Oncology, Sanofi, Cambridge, Massachusetts.
  • Castell C; Department of Translational Medicine, Sanofi, Vitry sur Seine, France.
  • Gomez C; Department of Drug Disposition, Sanofi, Alfortville, France.
  • Cartot-Cotton S; Department of Drug Disposition, Sanofi, Alfortville, France.
  • Mazuir F; Department of Drug Disposition, Sanofi, Alfortville, France.
  • Dubar M; Department of Translational Informatics, Sanofi, Chilly-Mazarin, France.
  • Micallef S; Department of Biostatistics Oncology, Sanofi R&D, Vitry sur Seine, France.
  • Demers B; Department of Oncology - Early Development, Sanofi, Vitry sur Seine, France.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Cancer ; 124(2): 315-324, 2018 01 15.
Article en En | MEDLINE | ID: mdl-28976556
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinonas / Inhibidores de las Quinasa Fosfoinosítidos-3 / Indoles / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinonas / Inhibidores de las Quinasa Fosfoinosítidos-3 / Indoles / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos